Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
placebo saline infusion (NuvOx Therapeutics)
- Development stage
- Unknown
- Lead developer
- NuvOx Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Placebo saline infusion refers to the control arm treatment used in NuvOx LLC's Phase II RESTORE clinical trial for patients with newly-diagnosed glioblastoma multiforme. In this randomized, double-blind study, the saline infusion is administered intravenously immediately prior to standard-of-care radiation therapy and temozolomide. It serves as a pharmacologically inactive comparator to NanO2 (dodecafluoropentane emulsion), an investigational oxygen therapeutic designed to sensitize hypoxic tumors to radiation. The use of a saline placebo ensures the maintenance of the study's blinding while providing a baseline for evaluating the safety and efficacy of the active treatment.
- Other names
- Placebo Saline InfusionSaline InfusionPlacebo
Beyond the preview
Go deeper on placebo saline infusion (NuvOx Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on placebo saline infusion (NuvOx Therapeutics).